Lupin Gains FDA Approval for Generic Sutab Tablets with 180-Day Exclusivity

For manufacturing and regulatory teams at Lupin, the clock on a finite competitive window has now started: the company has received FDA approval for its generic version of Sutab® Tablets, the sodium sulfate-based bowel preparation agent developed by Azurity Pharmaceuticals, with a 180-day exclusivity period attached to the ANDA.

That exclusivity designation is a material operational signal, not merely a commercial one. Under 21 CFR Part 314, first-filer exclusivity compresses the timeline in which plant heads and supply-chain leads must achieve validated commercial-scale output before competing ANDAs can enter the market. For a solid oral dosage form in the GI segment, that means process validation batches, released stability data, and distribution readiness must align within a window that offers no extension for manufacturing delays.

The GI-segment generics pipeline has drawn sustained ANDA activity in recent years, partly because branded bowel preparation products carry defined patient populations and predictable seasonal demand curves. For QA directors, the approval also signals that Lupin's submitted data package, covering formulation equivalence, dissolution profiling, and any relevant ICH Q10 quality system documentation, cleared FDA scrutiny without a complete response letter, a prerequisite before any commercial batch release can proceed.

Lupin has not disclosed the manufacturing site designated on the approved ANDA, nor has it confirmed launch timing. Given the 180-day exclusivity structure, the interval between approval and first commercial shipment will be closely watched by competing ANDA filers whose own approvals are contingent on exclusivity expiry.

The measurable outcome to track is the date of first commercial sale, which formally triggers the 180-day exclusivity clock under Hatch-Waxman and sets the re-entry point for all subsequent generic entrants in this segment.

Source: Media4Growth via Indian Pharma Post, 29 May 2026.